Certified by Founder Lodge
OrbiMed
United States - New York, NY
INVESTOR
1 Disclosed Funding Rounds $261,000,000
300 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit f
| Company | Date | Round | Raised |
|---|---|---|---|
 Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
 Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
 Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
 Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
 Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
 Fore Biotherapeutics |
August, 25 ,2023 | Series D | $75,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
 Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Fore Biotherapeutics |
August, 25 ,2023 | Series D | $75,000,000 |
 ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
 Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
 Star Therapeutics |
September, 05 ,2023 | Series C | $90,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
 Rampart Bioscience |
October, 25 ,2023 | Series A | $85,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Star Therapeutics |
September, 05 ,2023 | Series C | $90,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Rampart Bioscience |
October, 25 ,2023 | Series A | $85,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Rampart Bioscience |
October, 25 ,2023 | Series A | $85,000,000 |
| Rampart Bioscience |
October, 25 ,2023 | Series A | $85,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
 Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Rampart Bioscience |
October, 25 ,2023 | Series A | $85,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Rampart Bioscience |
October, 25 ,2023 | Series A | $85,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
 Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Rampart Bioscience |
October, 25 ,2023 | Series A | $85,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
 Epigenic Therapeutics |
August, 30 ,2023 | Series A | $32,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Rampart Bioscience |
October, 25 ,2023 | Series A | $85,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Epigenic Therapeutics |
August, 30 ,2023 | Series A | $32,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
 Pathalys Pharma |
February, 07 ,2023 | Unknown | $150,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Pathalys Pharma |
February, 07 ,2023 | Unknown | $150,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
 Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Epigenic Therapeutics |
August, 30 ,2023 | Series A | $32,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Epigenic Therapeutics |
August, 30 ,2023 | Series A | $32,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
 CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Epigenic Therapeutics |
August, 30 ,2023 | Series A | $32,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Epigenic Therapeutics |
August, 30 ,2023 | Series A | $32,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Pathalys Pharma |
February, 07 ,2023 | Unknown | $150,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Fore Biotherapeutics |
August, 25 ,2023 | Series D | $75,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Pathalys Pharma |
February, 07 ,2023 | Unknown | $150,000,000 |
| Pathalys Pharma |
February, 07 ,2023 | Unknown | $150,000,000 |
| Fore Biotherapeutics |
August, 25 ,2023 | Series D | $75,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Pathalys Pharma |
February, 07 ,2023 | Unknown | $150,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Epigenic Therapeutics |
August, 30 ,2023 | Series A | $32,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Epigenic Therapeutics |
August, 30 ,2023 | Series A | $32,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Fore Biotherapeutics |
August, 25 ,2023 | Series D | $75,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Fore Biotherapeutics |
August, 25 ,2023 | Series D | $75,000,000 |
| Pathalys Pharma |
February, 07 ,2023 | Unknown | $150,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Pathalys Pharma |
February, 07 ,2023 | Unknown | $150,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
 Pinnacle Medicines |
March, 27 ,2026 | Series B | $89,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
 Terremoto Biosciences |
April, 16 ,2026 | Series C | $108,000,000 |
| Pinnacle Medicines |
March, 27 ,2026 | Series B | $89,000,000 |
| Terremoto Biosciences |
April, 16 ,2026 | Series C | $108,000,000 |
dezerv.
FalconX
Kristal.AI
Finary
Savart
Jupid | $840,000 | (May 1, 2026)
DISA Technologies, Inc. | $33,000,000 | (May 1, 2026)
Blomma | $5,000,000 | (May 1, 2026)
Illuminant Surgical | $8,400,000 | (May 1, 2026)
Dreambase | $3,700,000 | (May 1, 2026)
